HIV-1 vaccine development aims to elicit broadly neutralizing antibodies (bnAbs) against diverse viral strains. In some HIV-1 infected individuals, bnAbs evolve from precursor antibodies through affinity maturation. To induce bnAbs, a vaccine must mediate a similar process of antibody maturation. One way to test vaccination strategies is to immunize mouse models that express human bnAb precursors. Such immunization experiments can assess whether the vaccine can convert precursor antibody into bnAb. A major problem with such mouse models is that bnAb expression often hinders B cell development in the bone marrow. Such developmental blocks may be attributed to unusual properties of bnAb variable regions, such as poly-reactivity and long antigen-binding loops, which are often under negative selection during primary B cell development. To address this problem, we devised a method to circumvent B cell developmental block by expressing bnAbs conditionally in mature B cells. We validated this method by expressing the unmutated common ancestor (UCA) of the human VRC26 bnAb in transgenic mice. Constitutive expression of combined immunoglobulin heavy and light chains of VRC26UCA led to developmental arrest of B cell progenitors in the bone marrow; poly-reactivity of VRC26UCA and poor pairing of VRC26UCA IgH chain with mouse surrogate light chain may contribute to the phenotype. The conditional expression strategy circumvented this developmental impediment, allowing the VRC26UCA to be expressed in mature peripheral B cells. This method should be generally applicable for expressing other antibodies that are under negative selection during B cell development.
Significance statement
Mouse models can provide fast and cost-effective systems to test HIV-1 vaccine candidates at the pre-clinical stage. To serve this purpose, mouse models are engineered to express the precursors of human bnAbs against diverse HIV-1 strains. Immunization of such mouse models can evaluate the ability of vaccines to mature the precursor antibodies into bnAbs. However, due to unusual properties of bnAbs, mouse models expressing their precursors often have B cell developmental defects. In this study, we devised and validated a strategy to address this problem. This method could also facilitate the expression of other clinically relevant antibodies in mature B cells in transgenic mice; immunization of such mice could be used to generate novel antibodies with desirable properties.
Introduction
Some HIV-1 infected individuals develop broadly neutralizing antibodies (bnAbs) against diverse viral strains (1, 2) . A goal of HIV-1 vaccine development is to elicit comparable bnAbs.
The bnAb developmental pathway during natural infection can serve as a blueprint for immunogen design. In bnAb donors, each bnAb lineage evolves from a germline antibody precursor, or unmutated common ancestor (UCA). The maturation of the UCA into a bnAb entails extensive somatic hypermutation. Conversion of UCA into bnAbs via vaccination may require a series of immunogens to guide the maturation process. These immunogens can be tested in transgenic mice that express bnAb precursor (3) .
To express bnAb precursors in transgenic mice, a standard method is to integrate, or knock-in (KI), the pre-assembled variable region (V(D)J) exons of the immunoglobulin (Ig) heavy (HC) and light chain (LC) of the antibody into mouse JH and Jk loci, respectively (3) . By allelic exclusion, pre-assembled V(D)J exons inhibit rearrangement of the endogenous Ig loci (4) , and, in theory, all B cells in the transgenic mice should express the KI antibody. A common problem with such KI mice is that B cells expressing certain bnAbs are deleted or anergized (5) (6) (7) (8) (9) (10) .
Such phenotypes are characteristic of B cells expressing auto-reactive antibodies. Some bnAbs are indeed poly-reactive or auto-reactive (11) (12) (13) (14) (15) (16) . Phenomena known as VH replacement and IgL receptor editing can allow selection of B cells that have deleted the HC and/or LC V(D)J exons of autoreactive antibodies and replaced them with endogenously assembled V(D)J exons (17) (18) (19) (20) (21) (22) . Clonal deletion or anergy can eliminate or inactivate autoreactive B cells (23) (24) (25) (26) (27) .
Exclusion from B cell follicles precludes autoreactive B cells from the compartment of recirculating mature B cells (28, 29) . These tolerance control mechanisms hinder the expression of bnAbs in KI mice (30) .
We have devised a method to overcome the developmental restriction on BnAb V(D)J KI alleles. For this purpose, we expressed a human bnAb UCA conditionally in mature B cells, thereby circumventing tolerance control checkpoints during B cell maturation. As a proof-ofprinciple experiment, we used this method to express the UCA of human VRC26 bnAb (31, 32) .
The VRC26 bnAb interacts with the V1V2 region at the apex of HIV-1 Envelop protein. The HC of VRC26 features an extraordinarily long complementarity determining region 3 (CDR H3), consisting of 37 amino acids. The long CDR H3 penetrates through thick glycan layer on HIV-1 Envelop to interact with a conserved peptide epitope underneath (33) . Antibodies with such a long CDR H3 is extremely rare in both human and mouse (34, 35) . Antibodies with long CDR H3s are often subject to negative selection during B cell development (36) . We anticipated similar obstacles for VRC26 expression in mice and confirmed this to be the case, allowing us to study the underlying cause and test our approach to address the problem.
Results
We constructed two mouse models for this study, constitutive and conditional expression models. In the constitutive expression model, V(D)J exons of the VRC26UCA HC and LC were integrated into mouse JH and Jk locus, respectively ( Fig.1A; Fig.S1 ). This conventional KI mouse could reveal negative selection against VRC26UCA and serve as a reference point for the conditional expression model. The design of the conditional expression model was adapted from a method to switch antibody V regions in memory B cells (37) . In this model, two V(D)J exons were integrated in tandem into the mouse JH locus ( Fig.1B; Fig.S1 ). The V(D)J exon proximal to the µ constant region (Cµ) derives from the IgH chain of a mouse antibody that promotes normal B cell development (38) . The intronic enhancer (iEµ), immediately downstream of the mouse V(D)J exon, should preferentially activate the expression of the mouse heavy chain (HC) over the VRC26UCA HC V exon inserted upstream. In addition, two polyadenylation sites truncate transcripts from the upstream VRC26UCA V exon (Fig.1C ).
These two measures ensure that the mouse HC is expressed in B cell progenitors and drives B cell maturation, without interference from VRC26UCA. For this reason, we refer to the mouse antibody as the "driver". Two loxP sites flank the driver V exon and polyadenylation sites (Fig.1C ). The mouse model also harbors a CD21-cre transgene (39) , which becomes active in mature B cells and excises the driver V(D)J exon and the polyadenylation sites. Consequently, VRC26UCA replaces the driver for expression in mature B cells. This strategy should enable VRC26UCA expression to bypass the B cell maturation block. The conditional expression method is applicable for both HC and LC. In the case of VRC26UCA, we hypothesized that the long CDR H3 would be the primary target for negative selection. To test this idea, we expressed the HC of VRC26UCA conditionally, but the LC constitutively ( Fig.1B ). In this situation, phenotypic differences between the conditional and constitutive models can be ascribed to differential HC expression.
B cell deletion in the constitutive expression model of VRC26UCA
We used allotypic markers to monitor VRC26UCA expression in the constitutive expression model. The two IgH alleles of the mouse model were derived from 129Sv and C57BL/6 mouse strains, respectively. The KI VRC26UCA HC resided on the IgH a allele from 129Sv strain; the IgH b allele from C57BL/6 strain was unmodified ( Fig.1A) . In naïve B cells, VRC26UCA HC was expressed as IgM a , whereas mouse HC was expressed as IgM b . In wildtype F1 mice, equal proportions of splenic B cells expressed IgM a or IgM b ( Fig.2A ) . Expression  of pre-rearranged V exons from IgH a allele should allelically exclude the IgH b allele; consequently, most B cells in such KI mice should express IgM a . The B1-8/3-83 KI mouse exemplified this phenomenon ( Fig.2B ). This mouse line harbors pre-rearranged V(D)J exons for the B1-8HC and 3-83LC at the JH and Jk loci, respectively (40, 41) . B1-8 is a mouse antibody against 4-hydroxy-3-nitrophenylacetyl hapten (42, 43) . 3-83 is a mouse antibody against H-2 k class I MHC (44) . The combination of B1-8HC and 3-83LC forms an innocuous antibody that supports B cell development (45) . Splenic B cells from B1-8/3-83 KI mouse expressed exclusively IgM a (Fig.2B ). By contrast, splenic B cells in the constitutive expression model of VRC26UCA expressed predominantly IgM b . In 7-week old mice, some IgM a B cells were detectable, but their surface IgM a levels were abnormally low ( Fig.2C ). By 37-weeks of age, even fewer B cells were IgM a+ (Fig.2D ). Another sign of a B cell anomaly was that VRC26UCA HC/LC mouse had reduced numbers of B cells in the spleen relative to F1 mouse (compare Fig.S2E and S2F with S2C). Using T cell numbers as an internal reference, the B/T ratio in F1 mouse was nearly 1.1; the ratio was reduced to 0.28 in 7-week old VRC26UCA HC/LC mouse.
A KI mouse with VRC26UCA HC alone had a similar, but less severe, phenotype ( The pattern of Ig light chain expression in the VRC26UCA KI mouse was also unusual.
Unlike IgH, Igk alleles in this model are not distinguishable by allotypic markers. Igk + B cells could express either VRC26UCA LC or a mouse LC, but all Igl + B cells expressed mouse LC.
In normal mice, about 3-5% of B cells expressed Igl, as shown in F1 mouse ( Fig.2E ). Because of allelic exclusion, expression of pre-rearranged VJ exon from the k locus, as in B1-8/3-83 KI mouse, further diminished Igl + B cells ( Fig.2F ). By contrast, the VRC26UCA KI mouse contained higher fractions of Igl + B cells than F1 mouse ( Fig.2G and 2H ). Within the Igl + population in a 7-week old mouse, some B cells expressed abnormally low levels of Igl ( Fig.2G ). These Igl lo B cells likely corresponded to those with low surface IgM a (Fig.2C ). In concert with the loss of IgM a B cells in older mice, Igl lo B cells also disappeared ( Fig.2H ).
Again, the KI mouse with VRC26UCA HC alone had a similar phenotype as the HC/LC mouse, but with a more prominent Igl lo population ( Figure 2M ), correlating with larger numbers of IgM a,lo B cells (Fig.2I ). The light chain loci were unmodified in the VRC26UCA HC mouse. The increase in Igl + B cells, and the distinct IgM a, lo Igl lo population, may reflect preferential pairing of VRC26UCA HC with the mouse l light chain. Expression of VRC26UCA LC also caused a noticeable increase in Igl + B cells, presumably due to deletion of the KI LC via receptor editing in some B cells ( Fig.2O and 2P ).
These analyses showed strong negative selection against VRC26UCA, primarily due to its heavy chain. VH replacement can delete rearranged V exons in IgH locus (17, 46) . Most VH segments contain a cryptic recombination signal sequence (RSS), which can undergo V(D)J recombination with upstream canonical RSSs to delete the KI V portion of the V(D)J exon and replace it with and upstream V sequence (17, 46) , To test whether VH replacement accounted for the loss of VRC26UCA HC expression, we generated hybridomas from splenic B cells of the constitutive mouse model. Consistent with the FACS analysis, the majority of hybridomas secreted IgM b allotype antibodies ( Fig.S3A and S3B ). Based on PCR analysis, all the examined hybridomas, including those expressing the IgM a allotype antibody, lost the region upstream of the cryptic RSS in VRC26UCA HC ( Fig.S3C and S3D ). Using a Digestion Circularization-PCR (DC-PCR) method, we identified the sequences that substituted for VRC26UCA HC in some hybridomas ( Fig.S3E -S3H, Table S1 ). These recombination products were typical VH replacement events, in which the cryptic RSS in VRC26UCA HC mediated V(D)J recombination with mouse VH and/or mouse D segments. In hybridomas producing IgM b allotype antibodies, the VH replacement products were nonproductive, including D to VRC26UCA HC rearrangements, out-of-frame VH-D-VRC26UCA HC rearrangements, or in-frame VH-D-VRC26UCA HC rearrangements with stop codons (Table S1). One IgG1 b hybridoma contained an in-frame VH-VRC26UCA HC recombination event. It is unclear why this HC was not expressed as an IgM a allotype antibody; one possibility is that the VH replacement product did not fold properly. In hybridomas producing IgM a allotype antibodies, VH-D-VRC26UCA HC recombination events were in-frame (Table S1 ). Thus, in all examined cases, VH replacement eliminated the VRC26UCA HC. the increase in Igl + B cells in VRC26UCA KI mouse. Deletion of the VRC26UCA LC via receptor editing could also result in the expression of the other Igk allele. Without an allotypic marker to distinguish the two Igk alleles, we could not assess the frequency of such events.
Thus, increase in Igl + B cells likely did not reflect the full extent of VRC26UCA LC deletion. As (Fig.3I ), the allotype of VRC26UCA HC, and CD93 hi , a marker for immature B cells Some bnAbs are poly-reactive, and expression of such antibodies can trigger tolerance control mechanisms (11) (12) (13) (14) (15) (16) . This mechanism could underlie the developmental arrest of immature B cells in VRC26UCA KI mouse. To test this possibility, we assessed the crossreactivity of VRC26UCA to mouse bone marrow and splenocytes. We prefer this assay to the conventional method of antibody staining of HEp2 cells (13) , which originated from human epithelial cells and does not represent relevant antigens for B cells in KI mice. For comparison, we used the driver mouse antibody, which was used to support B cell maturation in the (48, 49) , which promotes the transition from pro-B cells to pre-B cells and terminates IgH rearrangement (50) (51) (52) (53) (54) (55) ; poor pairing of VRC26UCA HC with SLC may lead to defects in both processes. To test this hypothesis, we co-transfected VRC26UCA HC with SLC components, VpreB (56) and l5 (57), into 293T cells. If the HC does not pair with SLC, the HC should not fold properly for secretion. Thus, the level of secreted HC, presumably in association with SLC, should correlate with their pairing efficiency. For comparison, we performed the same experiment with two mouse HCs: the driver HC and B1-8 HC ( Fig.4G and Fig.S6 ). In support of our prediction, cotransfection of VRC26UCA HC with mouse SLC yielded no detectable HC secretion, in contrast to the results with driver HC and B1-8 HC (Fig.4G ). The pairing defect was specific for mouse SLC, as co-transfection of VRC26UCA HC and LC led to robust antibody secretion ( Fig.4H ).
Furthermore, co-transfection of VRC26UCA HC with human SLC also improved antibody secretion ( Fig.4I ), and human l5 accounted primarily for the stimulatory effect ( Fig.4J and 4K ).
Conditional expression strategy to overcome B cell developmental block
The second goal of this study was to test whether a conditional expression strategy could overcome impediment to B cell development associated with constitutive expression of VRC26UCA. Toward this goal, we generated a conditional expression model of VRC26UCA Conditional expression of VRC26UCA depends on deletion of the driver V exon by CD21-cre ( Fig.1C ). Due to partial deletion, the IgM a B cell population consisted of a mixture of VRC26UCA and driver expressing B cells. To determine the ratio of these two types of B cells, we used the same DC-PCR method as for VH replacement analysis ( Fig.S8 ). Because of its long CDR H3, the DC-PCR product for VRC26UCA HC is longer than that of the driver HC (Fig.6G ). This result showed that VRC26UCA expressing B cells can at least be activated in vitro. Furthermore, the analysis confirmed the expression of VRC26UCA at the RNA level in a substantial fraction of splenic B cells, in corroboration with the DC-PCR analysis. As a validation of the conditional expression strategy, we also confirmed that VRC26UCA expression was dependent on driver deletion (Fig.S9 ).
Discussion
We (61). It is possible that long CDR H3, at least in some cases, structurally clashes with the non-Ig domain of the SLC. The 37 amino acid CDR H3 of VRC26UCA is far above the average CDR H3 length of mouse antibodies, and the mouse SLC may not be adapted to accommodating such extraordinarily long CDR H3s. By comparison, antibodies with long CDR H3s are more common in human than in mouse repertoires (34, 35, 62) . The difference may explain more efficient pairing of VRC26UCA HC with human SLC than with mouse SLC. To test the physiological relevance of these in vitro observations, an obvious experiment is to swap mouse SLC with human counterpart and determine whether human SLC facilitates B cell maturation in this and potentially other bnAb mouse models. Besides testing our hypothesis outlined above, the measure could also alleviate B cell developmental defects in other bnAb KI mice (5-10).
One implication this study is that multiple factors may contribute to B cell defects in bnAb KI mice. Some of these factors, such as a non-physiological B cell developmental pathway and mouse SLC pairing defect are specific to the KI mouse system and may not be relevant to human vaccination. Eliminating these non-physiological factors would not only increase target B cells for immunogens, but also reveal physiologically relevant hurdles for bnAb induction, and the information could facilitate the development of intervention strategies. The conditional expression approach is one step in this direction. The method bypasses the obstacles at the B cell progenitor stage, including some potentially non-physiological hindrances, and generates mature B cells expressing the target antibody for testing immunogens. In the case of the conditional expression model of VRC26UCA, the mature B cells express abnormally low levels of surface Ig and may be functionally anergic. Activating such B cells will likely be challenging.
On the other hand, if the anergic state reflects bona fide peripheral tolerance, the model could be used to develop strategies to revitalize the anergic B cells, for example with multimeric immunogens or potent adjuvants. Given the prevalence of poly-reactivity among bnAbs, such intervention may be necessary for bnAb induction (30, 63) . The conditional expression method is obviously not a feasible way to overcome deletion of bnAb precursors in humans. The value of the strategy lies in generating mouse models with sufficient target B cells for testing and optimizing immunization strategies at the preclinical stage. In human vaccination, an effective vaccine most likely will need to activate rare target B cells that have survived tolerance control checkpoints or other restrictions. Vaccine optimization in the model system we describe here, or in related mouse model systems, may increase the chance of success in overcoming such potential hurdles.
Materials and Methods

Generation of constitutive and conditional expression model of VRC26UCA
The conditional expression system requires a CD21-cre transgene. To expedite the setup of the conditional expression system, we derived an ES cell line from CD21-cre transgenic mice (39) . The genetic background of the original CD21-cre transgenic mouse line is C57BL/6. As described in the text, we planned to utilize IgH allotypic markers to differentiate B cells expressing KI VRC26UCA antibody versus mouse antibodies. Toward this end, we crossed the CD21-cre mice with 129Sv mice and derived an ES cell line from 3.5-day embryo.
In this CD21-cre ES cell line, one IgH allele is a allotype from 129/Sv mouse strain, whereas the other IgH allele is b allotype from C57BL/6 mouse strain. We used this CD21-cre ES cell line for incorporating VRC26UCA HC and LC expression constructs.
The organization of the integration construct for VRC26UCA HC is illustrated in Fig.S1A ; the diagram also applies to the LC KI construct. The homology arms of the integration constructs were amplified with high-fidelity PCR from the genomic DNA of an 129Sv ES cell line. Linearized construct was electroporated into the CD21-cre ES cell line described above.
Clones with stable integration of the construct were selected with G418. These clones were screened by Southern blotting. Correct clones were transduced with Adeno-cre virus. As illustrated in Fig.S1A , partial recombination with the three loxP sites in the construct gave rise to ES clones for either constitutive expression or conditional expression of VRC26UCA. LoxP recombination pattern was determined by Southern blotting. From this screening, we selected ES clones for constitutive or conditional expression of VRC26UCA. All clones for generating mouse models were verified for genotype ( Fig.S1B and S1C) and karyotype (96% ES cells with 40 chromosomes for the conditional expression model; 90% ES cells with 40 chromosomes for the constitutive expression model).
To generate the KI mice, the ES cells were injected into Rag2 deficient blastocysts.
Since Rag2 is essential to V(D)J recombination, B and T cells in the chimeric mice are derived from the injected ES cells, but not from the blastocysts. Thus, the chimeric mice can be used directly for analysis of KI antibody expression and B cell development. We refer to this technique as Rag2 deficient blastocyst complementation (RDBC) (64) . For long-term studies, we also bred the chimeric mice for germline transmission. In the present study, all analyses of the constitutive expression model were performed with germline KI mice that resulted from cross between VRC26UCA KI mice and C57BL/6 mice. These mice are of mixed 129Sv and C57BL/6 genetic background; the KI VRC26UCA HC was expressed as IgH a , whereas mouse antibodies were IgH b . The conditional expression model also gave germline transmission.
However, presumably due to leaky expression of CD21-cre in germ cells, the driver V gene flanked with loxP sites (floxed Driver) tended to be deleted in a substantial fraction of progenies during breeding. This issue compounded the difficulty of obtaining mice with genetic modifications on three chromosomes (HC KI, LC KI, CD21-cre) by breeding. For this reason, we used RDBC chimeric mice for the analysis of the conditional expression model.
Characterization of splenic and bone marrow B cells in mouse models
For splenic B cell analysis, spleen was dissociated mechanically into cell suspension.
Red blood cells were eliminated by Red Blood Cell lysing buffer (Sigma R7757). To generate the data in Fig.2, Fig.S2, and Fig.5 , the splenocytes were stained with the following antibodies: 
Analysis of VH replacement
Splenocytes were isolated from a constitutive expression model of VRC26UCA and stimulated with anti-CD40 antibody (Invitrogen 16-0402-86) plus IL4 (65) . After 3 days of stimulation, activated B cells were fused with NS1 plasmacytoma cells with the PEG method (66) . Hybridoma clones were selected with HAT. Supernatants from the hybridoma clones were screened via ELISA to determine the isotype and allotype of secreted antibodies.
Simulation with anti-CD40 plus IL4 induces class switching to IgG1 and IgE (65) . Unswitched B cells continue to express IgM. As a result, most of the hybridoma clones secreted IgM, IgG1 or IgE. Some supernatants contained more than one antibody isotype; these samples may be derived from mixed hybridoma clones and were not used for further analysis. Hybridoma clones producing only IgM or IgG1 were used for the experiments in Fig.S3 . The supernatants from these hybridomas were further screened with allotype-specific antibodies. For IgM + hybridomas, their supernatants were screened with anti-IgM a and anti-IgM b antibodies.
Hybridoma clones expressing only IgM a or IgM b were chose for further analysis. For IgG1 + hybridomas, their supernatants were screened with anti-IgG1 a antibody only; the anti-IgG1 b antibody works poorly in ELISA assays. IgG1 a-/IgG1 + hybridomas were considered as IgG1 b+ .
Without direct identification of IgG1 b hybridomas, some IgG1 a+ hybridomas could be mixed with IgG1 b+ hybridomas, causing over-estimation of the frequency of IgG1 a hybridomas.
In Fig.S3C , genomic DNAs from IgM + hybridomas were amplified with primers that anneal to sequences downstream of the cryptic RSS. In Fig.S3D , the same DNA samples from and XbaI. The ligated product was subject to PCR amplification with primers e and f (Fig.S3E ).
The PCR product was sequenced. The identities of the mouse D or VH segments joined to VRC26UCA HC, as shown in Fig.S3F, S3G , and S3H and Table S1, were determined with Blast or Ig Blast.
Assessment of cross-reactivity of VRC26UCA antibody
To produce recombinant VRC26UCA antibody and the driver antibody, the cDNAs for the heavy and light chains of these antibodies were cloned into pcDNA3 expression vector. The constant regions for the heavy and light chains were mouse µ and k isotypes, respectively. A 6xHis tag was appended to the C-terminus of the heavy chain to facilitate purification. The expression constructs were transfected into Expi293 cells, using ExpiFectamine (Gibco Hybridomas were generated and screened with the same method as that for the constitutive model, as described above. Fig.S9 shows the analysis of 8 IgG1 + hybridomas. As illustrated in the diagram above each gel image, RT-PCR amplification of driver or VRC26UCA HC transcripts were achieved with forward primers specific for each variable region and reverse primer in Cg1. PCR amplification of the driver HC or VRC26UCA HC directly from hybridoma DNA was achieved with forward primers specific for each variable region and a reverse primer downstream of JH. All the plots were gated on B cells. The gating strategy was illustrated in Fig.S4 . The plots were labeled in the same manner as those in Fig.2 ; bone marrow in this figure and spleen in Figure 2 for each genotype were isolated from the same mouse. cells. These two populations differ in size in VRC26UCA KI mice; to compensate for this disparity, the y-axis was normalized to mode, and the highest peak in each distribution is set to 100%. Due to smoothening of the curve, the highest peak may not be visible in some plots. FACS plots A-D in this figure were based on analysis of bone marrow from F1 mouse shown in Fig.3A , which was derived from the B220 + gate in plot D. All FACS plots in Fig.4 were based on the same gating strategy. The digested DNA was ligated with an adaptor for NcoI and EcoRI sites into circles. The circular DNA was subject to PCR amplification with primers a and b. The PCR reaction yielded products that contained the variable regions of either driver HC or VRC26UCA HC. The PCR products were run on agarose gel and detected by Southern blotting (Fig.6B and 6D). (B) To determine the ratio of driver HC and VRC26UCA HC, the DC-PCR method must amplify the two variable regions equally. To validate this point, genomic DNA was isolated from the liver of a mouse that was heterozygous for constitutive and conditional expression alleles of VRC26UCA.
Figure legends
The driver V region in the conditional expression cassette was not deleted in liver cells. In this DNA sample, the template ratio for driver HC and VRC26UCA HC in DC-PCR assay should be 1:1. After DC-PCR, the products were run on an agarose gel: M, 1kb DNA ladder; lane 1, DC-PCR without ligation adaptor, lane 2, DC-PCR with ligation adaptor. Due to its extraordinarily long CDR H3, the PCR product for VRC26UCA HC was longer than that for the driver HC; the identities of the PCR products were confirmed with sequencing. In correlation with input DNA, the DC-PCR reaction yielded equal amounts of products for driver HC and VRC26UCA HC. This table listed VH replacement products that were isolated from the hybridomas. The recombination took place between mouse VH and D segments with the KI VRC26UCA HC on IgH a allele from 129Sv mouse strain. The IgH locus from the 129Sv mouse strain has not been completely annotated. The VH and D segments in the table were the best matches from the IMGT data bases. Since the analysis was intended to illustrate the structure of VH replacement product, the precise identities of the gene segments were not critical.
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